Biogen Inc. (BIIB)
Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ:BIIB) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Biogen Inc. securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period").
Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.
BIOGEN CASE ALERT: Biogen Inc. (BIIB) Investors that Suffered Losses are Encouraged to Contact BFA Law About Approaching July 2024 Legal Deadline
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting Click Here
BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ:BIIB) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Biogen Inc. securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period").
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ:BIIB) and certain officers. The class action, filed in the United States District Court for the District of Colorado, and docketed under 24-cv-01444, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biogen securities between February 3, 2022 and February 13, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm
RADNOR, PA / ACCESSWIRE / June 9, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP(www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc. ("Biogen") (NASDAQ:BIIB). The action charges Biogen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.
